Shots:
- The NMPA has granted BTD to amdizalisib for the treatment of r/r FL
- The preliminary results from the ongoing P-Ib expansion study showed that the therapy was well- tolerated, exhibit dose-proportional PK, manageable toxicity profile, clinical activity in r/r B-cell lymphoma & results will be presented at ESMO 2021. Currently, the company gains all rights to amdizalisib globally
- The therapy is also being evaluated in an ongoing P-I/Ib study for patients with r/r NHL in the US & EU. In April’21, the company has initiated a P-II registration study for amdizalisib in ~100 patients with r/r FL & ~80 patients with MZL across 35 sites in China
Click here to read full press release/ article | Ref: Hutchmed | Image: Globe Newswire
The post Hutchmed’s Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China first appeared on PharmaShots.
